1. A province-wide HIV initiative to accelerate initiation of treatment-as-prevention and virologic suppression in British Columbia, Canada: a population-based cohort study.
- Author
-
Nanditha NGA, Dong X, Tafessu HM, Wang L, Lu M, Barrios R, Montaner JSG, and Lima VD
- Subjects
- Adult, British Columbia epidemiology, Cohort Studies, Early Diagnosis, Female, Humans, Male, Outcome and Process Assessment, Health Care, Sustained Virologic Response, Antiretroviral Therapy, Highly Active methods, Antiretroviral Therapy, Highly Active statistics & numerical data, HIV Infections epidemiology, HIV Infections therapy, Post-Exposure Prophylaxis methods, Post-Exposure Prophylaxis organization & administration, Preventive Health Services methods, Preventive Health Services organization & administration, Time-to-Treatment organization & administration, Time-to-Treatment standards
- Abstract
Background: In 2010, HIV treatment as prevention (TasP), encompassing widespread HIV testing and immediate initiation of free antiretroviral treatment (ART), was piloted under the Seek and Treat for Optimal Prevention of HIV/AIDS initiative (STOP) in British Columbia, Canada. We compared the time from HIV diagnosis to treatment initiation, and from treatment initiation to first virologic suppression, before (2005-2009) and after (2010-2016) the implementation of STOP., Methods: In this population-based cohort study, we used longitudinal data of all people living with an HIV diagnosis in BC from 1996 to 2017. We included those aged 18 years or older who had never received ART and had received an HIV diagnosis in the 2005-2016 period. We defined the virologic suppression date as the first date of at least 2 consecutive test results within 4 months with a viral load of less than 200 copies/mL. Negative binomial regression models assessed the effect of STOP on the time to ART initiation and suppression, adjusting for confounders. All p values were 2-sided, and we set the significance level at 0.05., Results: Participants who received an HIV diagnosis before STOP ( n = 1601) were statistically different from those with a diagnosis after STOP ( n = 1700); 81% versus 84% were men ( p = 0.0187), 30% versus 15% had ever injected drugs ( p < 0.0001), and 27% versus 49% had 350 CD4 cells/μL or more at diagnosis ( p < 0.0001). The STOP initiative was associated with a 64% shorter time from diagnosis to treatment (adjusted mean ratio 0.36, 95% confidence interval [CI] 0.34-0.39) and a 21% shorter time from treatment to suppression (adjusted mean ratio 0.79, 95% CI 0.73-0.85)., Interpretation: In a population with universal health coverage, a TasP intervention was associated with shorter times from HIV diagnosis to treatment initiation, and from treatment initiation to viral suppression. Our results show accelerating progress toward the United Nations' 90-90-90 target of people with HIV who have a diagnosis, those who are on antiretroviral therapy and those who are virologically suppressed, and support the global expansion of TasP to accelerate the control of HIV/AIDS., Competing Interests: Competing interests: Julio Montaner has received institutional grants from Gilead Sciences and Merck. No other competing interests were declared., (© 2022 CMA Impact Inc. or its licensors.)
- Published
- 2022
- Full Text
- View/download PDF